Efficacy and safety of biosimilar rituximab (ZytuxTM) in newly diagnosed patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia

Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL) are considered parts of mature B cell neoplasms in WHO classification. They are both characterized by accumulation of B cells in blood, lymphoid tissues and bone marrow. Most of treatment protocols of NHL and CLL contain rituximab in...

Descripción completa

Detalles Bibliográficos
Autores principales: Alwan, Alaa Fadhil, Abdulsahib, Manal Ali, Abbas, Duaa Dhahir, Abdulsattar, Saraa Ali, Ensaif, Reem Talib
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications, Pavia, Italy 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7731663/
https://www.ncbi.nlm.nih.gov/pubmed/33324477
http://dx.doi.org/10.4081/hr.2020.8296

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7731663/
https://www.ncbi.nlm.nih.gov/pubmed/33324477
http://dx.doi.org/10.4081/hr.2020.8296

Ejemplares similares